Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.

[1]  J. Kigawa,et al.  Checkpoint Kinase Inhibitor AZD7762 Overcomes Cisplatin Resistance in Clear Cell Carcinoma of the Ovary , 2014, International Journal of Gynecologic Cancer.

[2]  A. D’Andrea,et al.  A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy , 2012, Journal of the National Cancer Institute.

[3]  H. Hollema,et al.  The role of ATM and 53BP1 as predictive markers in cervical cancer , 2012, International journal of cancer.

[4]  M. Broggini,et al.  Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations. , 2011, European journal of cancer.

[5]  L. Pearl,et al.  CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. , 2011, Cancer research.

[6]  Douglas A Lauffenburger,et al.  A mammalian functional-genetic approach to characterizing cancer therapeutics. , 2010, Nature chemical biology.

[7]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[8]  T. Ward,et al.  Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors , 2010, British journal of pharmacology.

[9]  S. Carr,et al.  A Mitotic Phosphorylation Feedback Network Connects Cdk1, Plk1, 53BP1, and Chk2 to Inactivate the G2/M DNA Damage Checkpoint , 2010, PLoS biology.

[10]  Y. Pommier,et al.  Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide] , 2009, Journal of Pharmacology and Experimental Therapeutics.

[11]  Kum Kum Khanna,et al.  Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair , 2009, Clinical Cancer Research.

[12]  H. Boezen,et al.  Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. , 2009, Gynecologic oncology.

[13]  N. Kato,et al.  The DNA Damage Sensors Ataxia-Telangiectasia Mutated Kinase and Checkpoint Kinase 2 Are Required for Hepatitis C Virus RNA Replication , 2008, Journal of Virology.

[14]  S. Ashwell,et al.  DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy , 2008, Clinical Cancer Research.

[15]  Shuang Huang,et al.  ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis* , 2008, Journal of Biological Chemistry.

[16]  T. Hamilton,et al.  Platinum Resistance: The Role of DNA Repair Pathways , 2008, Clinical Cancer Research.

[17]  B. Zhivotovsky,et al.  DNA damage induces two distinct modes of cell death in ovarian carcinomas , 2008, Cell Death and Differentiation.

[18]  M. Garrett,et al.  CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin? , 2007, Nature Reviews Cancer.

[19]  M. Sarbia,et al.  The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus , 2007, British Journal of Cancer.

[20]  J. Wu,et al.  Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2 , 2007, Molecular Cancer Therapeutics.

[21]  Y. Shiloh,et al.  Differential Roles of ATM- and Chk2-Mediated Phosphorylations of Hdmx in Response to DNA Damage , 2006, Molecular and Cellular Biology.

[22]  Jacqueline A. Hall,et al.  Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies , 2006, British Journal of Cancer.

[23]  A. Ashworth,et al.  Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy , 2006, Clinical Cancer Research.

[24]  M. Szwerc,et al.  CHK-2 expression in lung cancer and tumor sensitivity to DNA damage-inducing therapy , 2005 .

[25]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[26]  Dimitris Kletsas,et al.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions , 2005, Nature.

[27]  E. Reed,et al.  Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells. , 2005, Biochemical and biophysical research communications.

[28]  Päivi Heikkilä,et al.  Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients , 2005, International journal of cancer.

[29]  J. Bartek,et al.  Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. , 2005, Experimental cell research.

[30]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[31]  Eddie Reed,et al.  CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer , 2004, Molecular Cancer.

[32]  Jiri Bartek,et al.  Targeting the checkpoint kinases: chemosensitization versus chemoprotection , 2004, Nature Reviews Cancer.

[33]  Jiri Bartek,et al.  Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.

[34]  T. Bessho.  Induction of DNA Replication-mediated Double Strand Breaks by Psoralen DNA Interstrand Cross-links* , 2003, The Journal of Biological Chemistry.

[35]  Jiri Bartek,et al.  53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer , 2002, Nature Cell Biology.

[36]  B. Gusterson,et al.  Concomitant inactivation of p53 and Chk2 in breast cancer , 2002, Oncogene.

[37]  P. McHugh,et al.  Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. , 2001, The Lancet. Oncology.

[38]  N. Mailand,et al.  The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis , 2001, Nature.

[39]  B. Nielsen,et al.  Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. , 1998, European journal of cancer.

[40]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.